All News

The pressing need for alternative energy sources is driving investment into nanotechnology devices for energy applications such as photovoltaic solar cells.

There’s a new kid on the block. How will the European Science Foundation justify its existence once the EU’s new pan European funding body moves into town?

China has now set its sights on developing its scientific prowess in the same way - and at the same rate – as it has modernised its economy.

Norwegian researchers want to commercialise an easy-to-use technology that diagnoses the cause of snoring and measures the effectiveness of treatments.

The academic community is in the middle of a massive debate on how people should be able to access the results of publicly funded research.

Imperial College London is set to become the first university to float its technology-transfer office directly on the stock market.

Less than 18 months since the policy was put in place, the UK government is reviewing progress on its approach to nanotechnology.

SMEs across Europe are backing to Framework Programme 7 - provided it avoids the funding pitfalls that emerged over the life of its predecessor.

This week the European Investment Fund took the first step in its ambitious new plan to unleash a wave of technology transfer across Europe. In doing so it endorsed a model pioneered in the UK.

Complying with the EU’s labyrinthine new REACH chemicals legislation was always going to be a tortuous process. For those who wait too long, it could be impossible.

On Tuesday the UK became the latest country to jump back on the nuclear energy bandwagon. But 20 years after Chernobyl, how easy is it to turn on the nuclear tap?

India's failure to launch a functional communications satellite using a home-grown rocket is likely to spur even more investment in space programmes.

The European Investment Fund has partnered with UK technology commercialisation company IP Group to form a venture capital fund to invest in university spin-outs.

French researchers have developed a cell therapy that could slash the risk of rejection after bone marrow grafts to under 5 per cent, and are looking for first-round funding.